hims glp 1 safe & Hers swings to a loss in Q1 amid shift in GLP-1 strategy Get after your goal weight

Strive Pharmacy settled a 2024 Arizona Board of Pharmacy consent agreement that included a $1,000 civil penalty related to semaglutide compounding and recordkeeping issues

The Sympathetic Nervous System in Heart Failure

The citrate it delivers is a natural inhibitor of calcium crystal formation

One major research goal is to separate appetite suppression from nausea

Discussion In this systematic review and meta-analysis, we included 10 studies

For currently approved GLP-1 receptor agonists available for weight management in the UK, NICE has established specific eligibility criteria: Semaglutide (Wegovy) NICE TA875 recommends semaglutide for adults with: A body mass index (BMI) of 35 kg/m or above with at least one weight-related comorbidity (such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity, prescribed only in specialist weight management services Evidence of previous unsuccessful weight loss attempts through diet, physical activity, and behavioural interventions Treatment is limited to a maximum of 2 years Liraglutide (Saxenda) NICE TA664 recommends liraglutide for adults with: A BMI of 35 kg/m or above (with or without comorbidities), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity Evidence of previous unsuccessful weight loss attempts Treatment is limited to a maximum of 2 years Both medications must be prescribed as part of a specialist weight management service providing multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions